Weber DM (2002) Newly diagnosed multiple myeloma. Curr Treat Options Oncol 3(3):235–245Donna M. Weber. (2002) Newly diagnosed multiple myeloma. Current Treatment Options in Oncology 3 , 235-245 /Donna M.Weber. (2002) Newly diagnosed multiple myeloma. Current Treatment Options in Oncology 3...
Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant. ...
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.As part of a CancerNetwork® Frontline Forum program, Joselle Cook, MBBS; Matthew James Pianko, MD; Luciano Costa, MD, PhD; and Timothy Schmidt,...
the Blood and Marrow Transplantation and Cell Therapy Program at the University of Alabama (UAB) Birmingham School of Medicine, and associate director for clinical research at the O’Neal Comprehensive Cancer Center at UAB, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma....
John Leonard, MD:So, from the standpoint of newly-diagnosed patients, the audience knows that transplant is clearly an important part of myeloma therapy. There are data looking at it. I know the IFM has some new studies on minimal residual disease and using that as a tool in the treatment...
For patients newly diagnosed with multiple myeloma in Oregon's Willamette Valley, our team of blood cancer specialists can walk you through what to expect
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)Clinical Presentation: FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizziness...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
The FDA has expanded the indication for lenalidomide to include newly diagnosed multiple myeloma patients.
Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862-868. doi:10.1001/jamaoncol.2021.0611ArticlePubMedGoogle Scholar...